We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Rachel
Westbrook
rachel.westbrook@nhs.net
Rachel
Westbrook
rachel.westbrook@nhs.net
Diseases of liver
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Acute-on-Chronic Liver Failure (ACLF) is a critical illness developing in some people with chronic liver disease who develop progressive organ failure with a high short-term mortality despite aggressive supportive care. To date, treatment options have been limited but Liver Transplantation (LT) is now recognised as a potential lifesaving treatment for some people with ACLF. However, it has limited availability and many uncertainties regarding its use for ACLF remain. Survival is inferior to standard elective LT and it is unclear how to identify those patients who will benefit from such surgery and those in whom it is futile, as they will inevitably die. We need to understand how best to match individual patients with an ideal liver graft, the detail of the physical and immunological processes that occur and what forms of pre- and post- operative care have the best survival. To do this we will perform a detailed study of people with severe ACLF (classified as Grades 2 and 3) who do and do not undergo LT, making additional comparison with people with severe liver disease but who have not progressed to develop ACLF.
The study is part of a global, prospective observational cohort study aimed at understanding the role of liver transplantation in patients with severe Acute on Chronic Liver Failure (ACLF). It will include 45 European LT centres and a total of 70-80 LT centres worldwide. It is coordinated and sponsored by The European Foundation for the Study of Chronic Liver Failure, (EFClif), in collaboration with the International Liver Transplantation Society (ILTS) and the European Liver and Intestine Transplant Association (ELITA).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
1. Acute or subacute liver failure without underlying cirrhosis. 2. Patients with hepatocellular carcinoma outside Milan criteria or other active neoplasia. 3. Subjects listed for transplantation other than liver or liver-kidney transplant. 4. Subjects with previous liver transplantation. 5. Vulnerable population (person under temporary or permanent guardianship or deprived of liberty by a judicial decision). 6. Pregnant and/or breastfeeding woman 7. Patients with relevant known comorbidities that could impact the prognosis: a. Subjects with very severe hepatopulmonary syndrome (with PaO2 < 50 mmHg on FiO2 21%) or moderate to severe portopulmonary hypertension (non-reversible mPAP > = 35 mmHg or PVR > = 500 dyn.s.cm-5 or 6.25 WU). b. Subjects with severe (grade IV) pulmonary disease (Global Obstructive Lung Disease [GOLD]). c. Subjects with chronic kidney disease requiring hemodialysis d. Subjects with severe heart disease (NYHA class III and IV) e. Subjects with a known infection with human immunodeficiency virus (HIV) f. Subjects with severe neurological or psychiatric disorders 8. Patients who cannot provide prior informed consent and when there is documented evidence that the patient has no personal consultee and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent. 9. Physician and team not committed to provide intensive care if needed.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by European Foundation for the Study of Chronic Liver Failure (EF-CLiF) and funded by European Foundation for the Study of Chronic Liver Failure (EF-CLiF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 48102
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
